Literature DB >> 11072940

Variant Creutzfeldt-Jakob disease in UK children: a national surveillance study.

C M Verity1, A Nicoll, R G Will, G Devereux, L Stellitano.   

Abstract

BACKGROUND: Variant Creutzfeldt-Jakob Disease (vCJD) was first reported in 1996; the youngest patient developed symptoms at 16 years of age. We have done 3 years of prospective active surveillance for progressive intellectual and neurological deterioration (PIND) in UK children, and have searched for vCJD among the children who were reported.
METHODS: Since May, 1997, there has been active surveillance for patients younger than 16 years old with PIND by means of a monthly card sent to all UK consultant paediatricians by the British Paediatric Surveillance Unit. Clinical'details of cases of PIND are obtained from reporting paediatricians by telephone interview or site visit, and an expert group of paediatric neurologists then classifies the cases.
FINDINGS: After 3 years, 885 patients with suspected PIND have been reported. Among them were two fatal cases of definite vCJD and one case of probable vCJD; all were reported in 1999. One girl was age 12 years at onset--the youngest ever case of vCJD. No other children with the clinical features of vCJD were identified. The expert group has discussed 655 cases, of which 360 have a confirmed underlying cause, being categorised into 88 known neurodegenerative diseases.
INTERPRETATION: That this prospective active surveillance in the UK has found few children with suspected vCJD is relatively reassuring. However, 3 years is a short time to survey a disease with an unknown incubation period. Since one probable and two definite cases of vCJD were reported to the study in 1999, there is concern that more childhood cases may appear.

Entities:  

Mesh:

Year:  2000        PMID: 11072940     DOI: 10.1016/s0140-6736(00)02785-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Neurological and cognitive decline in adolescence.

Authors:  Rob J Forsyth
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

2.  No clinical evidence of hidden vCJD in UK children.

Authors:  C M Verity; A M Winstone; L Stellitano; A Nicoll; R G Will
Journal:  Arch Dis Child       Date:  2005-10-31       Impact factor: 3.791

Review 3.  Surveillance for rare disorders by the BPSU. The British Paediatric Surveillance Unit.

Authors:  C Verity; M Preece
Journal:  Arch Dis Child       Date:  2002-10       Impact factor: 3.791

4.  The Canadian Paediatric Surveillance Program: Beyond collecting numbers.

Authors:  J A Doherty; D Grenier
Journal:  Paediatr Child Health       Date:  2001-05       Impact factor: 2.253

Review 5.  Presenile dementia syndromes: an update on taxonomy and diagnosis.

Authors:  M D Greicius; M D Geschwind; B L Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

Review 6.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

7.  Failure to detect the presence of prions in the uterine and gestational tissues from a Gravida with Creutzfeldt-Jakob disease.

Authors:  Xiangzhu Xiao; Leticia Miravalle; Jue Yuan; John McGeehan; Zhiqian Dong; Robert Wyza; Gregory T MacLennan; Alan M Golichowski; Geoff Kneale; Nicholas King; Qingzhong Kong; Salvatore Spina; Ruben Vidal; Bernardino Ghetti; Karen Roos; Pierluigi Gambetti; Wen-Quan Zou
Journal:  Am J Pathol       Date:  2009-04-06       Impact factor: 4.307

8.  Variations in neurodegenerative disease across the UK: findings from the national study of Progressive Intellectual and Neurological Deterioration (PIND).

Authors:  G Devereux; L Stellitano; C M Verity; A Nicoll; R G Will; P Rogers
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

9.  Understanding and exploiting interactions between cellular proteostasis pathways and infectious prion proteins for therapeutic benefit.

Authors:  Unekwu M Yakubu; Celso S G Catumbela; Rodrigo Morales; Kevin A Morano
Journal:  Open Biol       Date:  2020-11-25       Impact factor: 6.411

10.  Surveillance for variant CJD: should more children with neurodegenerative diseases have autopsies?

Authors:  Christopher Verity; Anne Marie Winstone; Robert Will; Alison Powell; Peter Baxter; Carlos de Sousa; Paul Gissen; Manju Kurian; John Livingston; Robert McFarland; Suvankar Pal; Michael Pike; Richard Robinson; Evangeline Wassmer; Sameer Zuberi
Journal:  Arch Dis Child       Date:  2018-10-18       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.